Loading
The chemotherapy given with radiation to cure anal cancer without surgery, used as a bladder instillation after tumour resection, and since 2020-25 in gel form for upper-tract and recurrent bladder cancers.
Approved 1974 (gastric, pancreatic). Anal SCC chemoradiation (Nigro, ACT II), intravesical single instillation after TURBT for NMIBC, hyperthermic intravesical and HIPEC use (appendiceal/PMP), ophthalmic antifibrotic. Mitomycin gel (Jelmyto, 2020) for low-grade upper-tract urothelial carcinoma and intravesical gel (Zusduri, 2025) for recurrent low-grade intermediate-risk NMIBC. Haemolytic uraemic syndrome and pulmonary toxicity at cumulative doses.
Reduced intracellularly to a bifunctional alkylator that cross-links DNA at CpG sites; preferentially activated in hypoxic cells, making it a radiosensitiser.
1.Mitomycin C slips into a pocket on its target.
Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. IV and intravesical mitomycin are generic Part B drugs. Jelmyto (pyelocalyceal) and Zusduri (intravesical, 2025) are branded, clinician-instilled products under Part B with higher coinsurance.
Multi-source generic; covered under the medical benefit without prior authorisation in most plans, as part of standard regimens. Jelmyto and Zusduri typically require prior authorisation.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.
Sources: NICE search: mitomycin C. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 1974 | Disseminated gastric or pancreatic adenocarcinoma (with other agents) |
| US | 2020 | Low-grade upper tract urothelial carcinoma (mitomycin pyelocalyceal gel) |
| US | 2025 | Recurrent low-grade intermediate-risk NMIBC (intravesical gel) |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
The standard-of-care rows on the appendiceal pages, particularly who is referred for cytoreductive surgery and who receives chemotherapy, follow this consensus and the NCCN appendiceal section.
Fluorouracil and mitomycin with radiotherapy remains the standard for localised anal cancer, without maintenance, and patients whose tumour has not vanished at three months should be watched to six months rather than sent straight to surgery.
Query for this drug: (TITLE:"Mitomycin C" OR ABSTRACT:"Mitomycin C" OR TITLE:"Mutamycin" OR ABSTRACT:"Mutamycin" OR TITLE:"Jelmyto" OR ABSTRACT:"Jelmyto" OR TITLE:"Zusduri" OR ABSTRACT:"Zusduri") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Mitomycin C, not a curated reading list.
Shares Netherlands Cancer Institute HIPEC trial, Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases,, Gastric & gastro-oesophageal junction cancer, Cytotoxic chemotherapy and the tag generic.
Shares Gastric & gastro-oesophageal junction cancer, Cytotoxic chemotherapy and the tag generic.
Shares Cytotoxic chemotherapy and the tag generic.
Shares Cytotoxic chemotherapy and the tag generic.
Shares Cytotoxic chemotherapy and the tag generic.
Shares Cytotoxic chemotherapy and the tag generic.
Shares Cytotoxic chemotherapy and the tag generic.
Shares Cytotoxic chemotherapy and the tag generic.